Lindbrook Capital LLC Has $615,000 Stake in AstraZeneca PLC (NASDAQ:AZN)

Lindbrook Capital LLC reduced its stake in AstraZeneca PLC (NASDAQ:AZN) by 8.1% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 7,889 shares of the company’s stock after selling 692 shares during the quarter. Lindbrook Capital LLC’s holdings in AstraZeneca were worth $615,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD increased its position in AstraZeneca by 17.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 61,271,974 shares of the company’s stock worth $4,151,177,000 after acquiring an additional 9,002,450 shares during the period. Capital World Investors lifted its stake in AstraZeneca by 0.3% during the first quarter. Capital World Investors now owns 9,365,676 shares of the company’s stock worth $634,525,000 after purchasing an additional 29,497 shares during the period. Envestnet Asset Management Inc. boosted its holdings in AstraZeneca by 16.7% during the second quarter. Envestnet Asset Management Inc. now owns 3,417,933 shares of the company’s stock valued at $266,565,000 after purchasing an additional 488,644 shares in the last quarter. Clearbridge Investments LLC grew its stake in shares of AstraZeneca by 5.8% in the 2nd quarter. Clearbridge Investments LLC now owns 3,403,748 shares of the company’s stock valued at $265,458,000 after purchasing an additional 186,010 shares during the period. Finally, Fayez Sarofim & Co raised its holdings in shares of AstraZeneca by 4.7% in the 1st quarter. Fayez Sarofim & Co now owns 2,990,234 shares of the company’s stock worth $202,588,000 after buying an additional 134,784 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on AZN shares. TD Cowen boosted their target price on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $89.75.

AstraZeneca Trading Down 0.3 %

Shares of AZN stock opened at $64.49 on Friday. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The company has a market capitalization of $199.96 billion, a PE ratio of 31.15, a price-to-earnings-growth ratio of 1.19 and a beta of 0.47. The firm has a 50 day moving average price of $77.07 and a two-hundred day moving average price of $78.56. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.